- Home
- HMY vs MRNA Comparison
HMY vs MRNA Comparison
Compare HMY & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HMY | MRNA |
|---|---|---|
| Founded | 1950 | 2010 |
| Country | South Africa | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4B | 11.5B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | HMY | MRNA |
|---|---|---|
| Price | $20.69 | $33.58 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 13 |
| Target Price | $16.00 | ★ $33.25 |
| AVG Volume (30 Days) | 4.1M | ★ 10.5M |
| Earning Date | 02-04-2016 | 11-06-2025 |
| Dividend Yield | ★ 0.81% | N/A |
| EPS Growth | ★ 67.74 | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $4,161,584,110.00 | $2,232,000,000.00 |
| Revenue This Year | $39.51 | N/A |
| Revenue Next Year | $14.06 | $0.77 |
| P/E Ratio | $15.72 | ★ N/A |
| Revenue Growth | ★ 20.39 | N/A |
| 52 Week Low | $7.97 | $22.28 |
| 52 Week High | $22.25 | $48.92 |
Technical Indicators
Market Signals| Indicator | HMY | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 63.63 | 77.92 |
| Support Level | $20.10 | $28.66 |
| Resistance Level | $20.80 | $30.44 |
| Average True Range (ATR) | 0.81 | 1.44 |
| MACD | 0.07 | 0.61 |
| Stochastic Oscillator | 77.69 | 93.51 |
Price Performance
Historical ComparisonAbout HMY Harmony Gold Mining Company Limited
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.